将前列腺多参数磁共振引入主动监测方案是否改善患者再分类?
该研究纳入2010-2016年445例接受主动监测的低体积低至中危前列腺癌患者,比较引入mpMRI±靶向活检前后的再分类与治疗触发情况。结果发现mpMRI±靶向活检较单纯活检更易再分类并识别需治疗的患者,但两组至治疗时间无显著差异。
要点
- mpMRI±靶向活检较单纯活检提高再分类率(44% vs 37%,P=0.003)。
- 两组至治疗时间无显著差异(中位1.9 vs 1.33年,P=0.747)。
- 最常见治疗触发为mpMRI及靶向活检后升级(29%)。
核心结论
- 以mpMRI±靶向活检替代系统穿刺活检作为主动监测方案的一部分,可提高再分类可能性并识别需治疗的临床显著疾病患者。
研究设计与样本
- 回顾性队列研究,纳入2010-2016年445例接受主动监测的低体积低至中危前列腺癌患者,中位随访2.4年(IQR 1.2-3.7)。
- 按2014年前方案(含前列腺穿刺活检)与2014年后NICE指南方案(含mpMRI)分组,并细分四组:无mpMRI无活检、单纯活检、mpMRI±靶向活检、活检联合mpMRI±靶向活检。
主要发现
- 445例中132例(30%)停止主动监测并接受治疗,中位至治疗时间1.55年(IQR 0.71-2.4)。
- 最常见治疗触发为mpMRI及靶向活检后前列腺癌升级(43/132例,29%)。
- 单纯活检组与mpMRI±靶向活检组至治疗时间无显著差异(中位1.9 vs 1.33年,P=0.747)。
- 仅接受重复活检者中,mpMRI后靶向活检组停止主动监测比例高于单纯活检组(29/66[44%] vs 32/87[37%],P=0.003)。
- 无论单纯活检还是靶向活检,平均需一组重复活检触发治疗。
临床怎么用
- 在主动监测方案中采用mpMRI±靶向活检有助于识别需治疗的临床显著前列腺癌患者。
- mpMRI±靶向活检作为主动监测的一部分,代表主动监测方案肿瘤学安全性的显著进步。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether replacement of protocol-driven repeat prostate biopsy (PB) with multiparametric magnetic resonance imaging (mpMRI) ± repeat targeted prostate biopsy (TB) when evaluating men on active surveillance (AS) for low-volume, low- to intermediate-risk prostate cancer (PCa) altered the likelihood of or time to treatment, or reduced the number of repeat biopsies required to trigger treatment. PATIENTS AND METHODS: A total of 445 patients underwent AS in the period 2010-2016 at our institution, with a median (interquartile range [IQR]) follow-up of 2.4 (1.2-3.7) years. Up to 2014, patients followed a 'pre-2014' AS protocol, which incorporated PB, and subsequently, according to the 2014 National Institute for Health and Care Excellence (NICE) guidelines, patients followed a '2014-present' AS protocol that included mpMRI. We identified four groups of patients within the cohort: 'no mpMRI and no PB'; 'PB alone'; 'mpMRI ± TB'; and 'PB and mpMRI ± TB'. Kaplan-Meier plots and log-rank tests were used to compare groups. RESULTS: Of 445 patients, 132 (30%) discontinued AS and underwent treatment intervention, with a median (IQR) time to treatment of 1.55 (0.71-2.4) years. The commonest trigger for treatment was PCa upgrading after mpMRI and TB (43/132 patients, 29%). No significant difference was observed in the time at which patients receiving a PB alone or receiving mpMRI ± TB discontinued AS to undergo treatment (median 1.9 vs 1.33 years; P = 0.747). Considering only those patients who underwent repeat biopsy, a greater proportion of patients receiving TB after mpMRI discontinued AS compared with those receiving PB alone (29/66 [44%] vs 32/87 [37%]; P = 0.003). On average, a single set of repeat biopsies was needed to trigger treatment regardless of whether this was a PB or TB. CONCLUSIONS: Replacing a systematic PB with mpMRI ±TB as part of an AS protocol increased the likelihood of re-classifying patients on AS and identifying men with clinically significant disease requiring treatment. mpMRI ±TB as part of AS thereby represents a significant advance in the oncological safety of the AS protocol.
引用
- Bryant RJ, Yang B, Philippou Y, et al. Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification? BJU Int. 2018. PMID: 29645347. doi:10.1111/bju.14248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。